Assessing treatment efficacy for interval-censored endpoints using multistate semi-Markov models fit to multiple data streams.

ABSTRACT: We introduce a computationally efficient and general approach for utilizing multiple, possibly interval-censored, data streams to study complex biomedical endpoints using multistate semi-Markov models. Our motivating application is the REGEN-2069 trial, which investigated the protective efficacy (PE) of the monoclonal antibody combination REGEN-COV against SARS-CoV-2 when administered prophylactically to individuals in households at high risk of secondary transmission. Using data on symptom onset, episodic RT-qPCR sampling, and serological testing, we estimate the PE of REGEN-COV for asymptomatic infection, its effect on seroconversion following infection, and the duration of viral shedding. We find that REGEN-COV reduced the risk of asymptomatic infection and the duration of viral sheddin

SUBMITTER: Morsomme R 

PROVIDER: S-EPMC12629085 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature